232 filings
Page 8 of 12
8-K
t0x5ukt0mfeh9
24 May 18
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
4:15pm
8-K
48owdm i0meii
13 Apr 18
Other Events
12:00am
8-K
e9m5g vs4ryp00
9 Mar 18
Submission of Matters to a Vote of Security Holders
12:00am
8-K
d7k1amyy2 wgb
22 Feb 18
ContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation
12:00am
8-K
536 v1yjdqkbmem
21 Feb 18
3 of 4 Proposals pass with stockholder approval
12:00am
8-K
7a59nw
12 Feb 18
ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway
12:00am
8-K
ojn1eo
9 Feb 18
ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference
12:00am
8-K
4kljr31s05cy
6 Feb 18
Other Events
12:00am
8-K
368u782
5 Feb 18
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Determination
12:00am
8-K
8hd9v
3 Jan 18
ContraVir Pharmaceuticals to Present at Biotech Showcase 2018
12:00am
8-K
jjco y98d71pklk
2 Jan 18
Other Events
12:00am
8-K
3n2d6j
21 Dec 17
Other Events
12:00am
8-K
srpurmgfkhq
18 Dec 17
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
taice7c
13 Dec 17
Other Events
12:00am
8-K
11u2t253ixtvpu5w cz
8 Dec 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
pkoy jvmlt2h46805
6 Nov 17
ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
12:00am
8-K
x045ys5
27 Oct 17
Reports 2017 Financial and Operational Results
12:00am
8-K
q3sib
24 Oct 17
ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431
12:00am
8-K
5ewcq8f
19 Oct 17
Other Events
12:00am
8-K
toqde9uzn tjq0
17 Oct 17
ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology
12:00am